These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 20814819

  • 1. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z, Thoms J, Ghosh S, Hanson J, Deschênes J, Sabri S, Abdulkarim B.
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [Abstract] [Full Text] [Related]

  • 2. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
    Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S.
    J Clin Oncol; 2011 Jul 20; 29(21):2852-8. PubMed ID: 21670451
    [Abstract] [Full Text] [Related]

  • 3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

  • 4. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.
    Eur J Surg Oncol; 2013 Mar 20; 39(3):260-5. PubMed ID: 23313014
    [Abstract] [Full Text] [Related]

  • 5. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
    Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris L, Wright JL.
    Breast Cancer Res Treat; 2011 Aug 20; 128(3):899-906. PubMed ID: 21475999
    [Abstract] [Full Text] [Related]

  • 6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 7. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.
    Zhonghua Zhong Liu Za Zhi; 2010 Jul 07; 32(7):520-5. PubMed ID: 21029696
    [Abstract] [Full Text] [Related]

  • 8. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E.
    Int J Radiat Oncol Biol Phys; 2005 Apr 01; 61(5):1337-47. PubMed ID: 15817335
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 01; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 16. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.
    Breast Cancer Res Treat; 2011 Jun 01; 127(3):713-20. PubMed ID: 21452022
    [Abstract] [Full Text] [Related]

  • 17. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, McCormick B, Powell SN, Ho AY.
    Ann Surg Oncol; 2015 Dec 01; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [Abstract] [Full Text] [Related]

  • 18. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
    Lupe K, Truong PT, Alexander C, Speers C, Tyldesley S.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):e681-8. PubMed ID: 21300456
    [Abstract] [Full Text] [Related]

  • 19. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
    Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, Yu BL, Lee MY, Chi CW.
    Int J Radiat Oncol Biol Phys; 2010 Jun 01; 77(2):516-22. PubMed ID: 19577858
    [Abstract] [Full Text] [Related]

  • 20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Jun 01; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.